匈牙利糖尿病视网膜病变医疗成本及2045年预测:基于可避免盲快速评估的方法
该研究基于RAAB+DRM方法和患病成本模型,估算匈牙利18岁及以上人群糖尿病视网膜病变(DR)的医疗总成本并预测2045年趋势。玻璃体腔抗VEGF注射和玻璃体切除术是主要成本驱动因素,占总治疗成本的86.7%。
要点
- 玻璃体腔抗VEGF注射和玻璃体切除术是主要成本驱动因素,占总治疗成本的86.7%。
- 匈牙利DR患者人均治疗成本为180.5美元,低于其他国家。
核心结论
- 匈牙利DR患者人均治疗成本低于其他国家。
- 增殖性DR和糖尿病相关失明的社会经济负担日益增加,投资于DR筛查、预防和早期治疗十分重要。
- 基于RAAB的DR成本模型有助于跨国比较DR治疗成本。
研究设计与样本
- 基于标准化可避免盲快速评估联合糖尿病视网膜病变模块(RAAB+DRM)方法开发成本模型。
- 采用近期报道的患病成本疾病模型,从医疗系统和患者视角分析成本。
- DR成本模型依据苏格兰DR分级标准和DR严重程度分期构建。
- 2045年预测基于国际糖尿病联盟(IDF)对糖尿病患病率增长的估计。
- 研究对象为匈牙利18岁及以上人群。
主要发现
- 匈牙利DR相关人均成本为180.5美元。
临床怎么用
- 应重视DR筛查、预防和早期治疗以应对增殖性DR和糖尿病相关失明的社会经济负担。
- 基于RAAB的DR成本模型可用于跨国DR治疗成本比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: The purpose of this study was to estimate the total healthcare cost associated with diabetic retinopathy (DR) in the population aged 18 years and older in Hungary, and its projection for the year 2045. METHODS: A cost model was developed based on the standardised rapid assessment of avoidable blindness with the diabetic retinopathy module (RAAB+DRM) methodology and recently reported prevalent-based cost of illness model. Projection for 2045 was made based on the estimation for increasing diabetes mellitus (DM) prevalence of the International Diabetes Federation. Costs were analysed from the perspective of the healthcare system and the patients. Our DR cost model was constructed according to the Scottish DR grading scale and based on the DR severity stadium. RESULTS: The total DR-associated healthcare cost was US$145.8 million in 2016 and will increase to US$169.0 million by 2045. The two major cost drivers were intravitreal antivascular endothelial growth factor injections and vitrectomies in this study (US$126.4 million in 2016 and US$146.5 million in 2045); they amounted to 86.7% of the total treatment cost of DR. The DR-related cost per patient was US$180.5 in Hungary. CONCLUSIONS: The cost per patient for treating DR was lower in Hungary than in other countries. Due to the increasing socioeconomic burden of proliferative DR and diabetes-related blindness, it would be important to invest in DR screening, prevention and early treatment. Our new RAAB-based cost of DR model may facilitate comparisons of DR treatment costs across countries.
引用
- Tóth G, Limburg H, Szabó D, et al. Rapid assessment of avoidable blindness-based healthcare costs of diabetic retinopathy in Hungary and its projection for the year 2045. Br J Ophthalmol. 2020. PMID: 32788328. doi:10.1136/bjophthalmol-2020-316337
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。